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ABSTRACT
BET bromodomain inhibitors, which have an antitumoral effect against various 
solid cancer tumor types, have not been studied in detail in luminal breast cancer, 
despite the prevalence of this subtype of mammary malignancy. Here we demonstrate 
that the BET bromodomain inhibitor JQ1 exerts growth-inhibitory activity in 
human luminal breast cancer cell lines associated with a depletion of the C-MYC 
oncogene, but does not alter the expression levels of the BRD4 bromodomain protein. 
Interestingly, expression microarray analyses indicate that, upon JQ1 administration, 
the antitumoral phenotype also involves downregulation of relevant breast cancer 
oncogenes such as the Breast Carcinoma-Amplified Sequence 1 (BCAS1) and the 
PDZ Domain-Containing 1 (PDZK1). We have also applied these in vitro findings in 
an in vivo model by studying a transgenic mouse model representing the luminal B 
subtype of breast cancer, the MMTV-PyMT, in which the mouse mammary tumor virus 
promoter is used to drive the expression of the polyoma virus middle T-antigen to the 
mammary gland. We have observed that the use of the BET bromodomain inhibitor for 
the treatment of established breast neoplasms developed in the MMTV-PyMT model 
shows antitumor potential. Most importantly, if JQ1 is given before the expected time 
of tumor detection in the MMTV-PyMT mice, it retards the onset of the disease and 
increases the survival of these animals. Thus, our findings indicate that the use of 
bromodomain inhibitors is of great potential in the treatment of luminal breast cancer 
and merits further investigation.
INTRODUCTION
Breast cancer is a leading cause of cancer death 
in women, estimated to account for more than 450,000 
deaths worldwide every year [1]. Despite the improved 
early detection of the disease and the new therapies, 
the major health concern associated with breast cancer 
persists probably due to several factors, among them 
the biological heterogeneity of the pathology. Classical 
clinical and pathological markers, such as the status 
of the estrogen and progesterone receptors and human 
epidermal growth factor 2 (HER2) gene amplification, 
are useful for classifying patients according to prognosis 
and adequate treatments, but it has been the emergence of 
genomic technologies, such as global expression profiling, 
that has allowed an intrinsic molecular classification 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 31), pp: 51621-51629
                     Research Paper
Oncotarget51622www.impactjournals.com/oncotarget
[2–4]. In this regard, five distinct intrinsic molecular 
subtypes are recognized: luminal A, luminal B, HER-
2 enriched, basal-like and claudin-low, together with a 
normal breast-like group [2–4]. These subgroups relate 
to the clinically used immunohistochemical classification 
and, for example, luminal A is estrogen receptor- and/
or progesterone receptor-positive but with a low Ki-
67 index, whereas luminal B is estrogen receptor- and/
or progesterone receptor-positive and high Ki-67 index. 
Overall, the majority of breast tumors are positive for 
the hormone receptors and, thus, amenable to endocrine 
therapies. However, in the natural history of the disease, 
progression is associated with the acquisition of resistance 
to the endocrine treatment, limiting the efficacy of these 
pharmacological compounds. In addition, the survival 
curves of luminal B subtype cross those of basal-like 
disease at ten years [4]. Thus, given the high frequency 
of luminal breast cancer, the generation of endocrine 
therapy-associated resistances and the poor outcome of 
the luminal B subtype, the development of new drugs for 
these patients is essential.
One interesting avenue to explore is the targeting 
of the epigenome of breast cancer cells. In this regard, 
DNA demethylating agents and histone deacetylase 
inhibitors have been clinically approved for certain 
subtypes of leukemias and lymphomas [5]. New 
promising agents are compounds that can block the 
“reading” of the acetylated histone marks, preventing 
the active transcription of growth-promoting genes. 
This is the case of the BET bromodomain inhibitors 
that remove BET bromodomain proteins from their 
chromatin targets by competing with acetylated histone 
residues [6]. The patterns of histone acetylation shifts 
in human tumors [7] and recent data have shown that 
the BET bromodomain inhibitor inhibits the growth of 
triple-negative breast cancer cell lines and xenografts 
[8–15]. Thus, we sought to determine whether BET 
bromodomain inhibitors were also effective not only 
in luminal breast cancer cell lines, but also in a mouse 
model of luminal B breast cancer (MMTV-PyMT) 
[16]. Furthermore, we also characterized gene targets 
involved in the antiproliferative effect mediated by the 
BET bromodomain inhibitor JQ1 [17].
RESULTS
The bromodomain inhibitor JQ1 decreases 
cell viability of human luminal breast cancer 
cell lines in association with downregulation of 
C-MYC and mammary oncogenic proteins
To study the cellular impact of JQ1 as a candidate 
growth inhibitor for luminal breast cancer, we chose 
the initial biological model of two human cancer cell 
lines with a well characterized luminal phenotype, 
MCF7 and T47D [18, 19]. Using the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay to measure cell viability in the chosen cancer 
cell lines, we observed that JQ1 inhibited cancer cell 
growth dose-dependently (Figure 1A). Interestingly, 
IC50 sensitivity to this first-in-class BET bromodomain 
inhibitor compound is in the same range as that of other 
antitumoral drugs that target histone modifications, such 
as histone deacetylases [20] and histone kinases [21, 22]. 
The next step was to show that the growth inhibition-
mediated effect of the JQ1 compound occurred in the 
context of the induced downregulation of C-MYC, as has 
been described in other models [23, 24]. Western blot 
and quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) demonstrated that JQ1 diminished 
C-MYC expression levels (Figure 1B) in both luminal 
breast cancer cell lines. As expected [17, 23, 24], the 
use of JQ1 did not modify the expression levels of the 
bromodomain protein BRD4, as also shown by western 
blot and qRT-PCR (Figure 1B).
We next sought to identify other gene targets that, 
in addition to the well characterized depletion of the 
C-MYC oncogene, could also explain the observed growth 
inhibitory effect of the use of the BET bromodomain 
inhibitor. We performed an expression microarray 
experiment in MCF7 and T47D cells treated with a 
vehicle compared with those in which we used the JQ1 
compound (Figure 2A). The expression microarray data 
have been deposited in the Gene Expression Omnibus 
(GEO) repository under Accession Number GSE95287. Of 
the set of 36,712 unique genes included in the microarray, 
1,149 (3.1%) significantly changed in a shared manner 
in both cell lines; 420 (36.6%) of them were upregulated 
and 729 (63.4%) were downregulated. The latter set 
constitutes the putative direct substrates of JQ1 that act 
by removing the BET bromodomain proteins from their 
regulatory regions through competition with acetylated 
histone residues that are usually associated with active 
transcription [6]. Gene functional annotation analysis 
for these transcripts was performed by computing gene 
overlapping with GSEA KEGG and GO signature 
collections. Among the 729 genes downregulated upon 
JQ1 use, we observed an overrepresentation of KEGG 
pathways and GO biological process terms related with 
pathways in cancer and regulation of cell proliferation, 
respectively (False Discovery Rate q-value <0.05) 
(Supplementary Figure 1 and Supplementary Table 1). 
Among the top candidate genes commonly downregulated, 
our attention was particularly drawn by the presence 
of the transcripts for the PDZ Domain-Containing 1 
(PDZK1) and the Breast Carcinoma-Amplified Sequence 
1 (BCAS1) genes, which encode two oncoproteins that 
have been linked to mammary tumorigenesis [25–28]. 
PDZK1 promotes estrogen-mediated growth of breast 
cancer cells [25, 26], whereas BCAS1 undergoes gene 
amplification-associated overexpression in breast cancer 
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[27] and has been implicated in breast cancer progression 
[28]. The downregulation of these transcripts upon JQ1 
administration was validated by qRT-PCR in the same 
RNA extracts as used for microarray hybridization (Figure 
2B) and when the experiment was repeated in a new batch 
of cells treated for different times (Figure 2C). We also 
assessed to what extent the effects of JQ1 are mediated by 
its silencing of C-MYC compared to PDZK1 and BCAS1. 
Upon efficient short hairpin RNA (shRNA) mediated 
dowregulation of MYC, PDZK1 or BCAS1 in MCF7 and 
T47D (Supplementary Figure 2A), we observed a similar 
significant decrease in the cell viability determined by the 
MTT assay (Supplementary Figure 2B and 2C). These 
data suggest that all three proteins exert a similar role as 
growth promoting factors in these luminal breast cancer 
cell lines. Importantly, the growth inhibition mediated 
Figure 1: JQ1 treatment of human luminal breast cancer cell lines reduces cell viability and downregulates C-MYC. 
(A) Effect of JQ1 on cell viability determined by the MTT assay in MCF7 and T47D cells. The corresponding half-maximal inhibitory 
concentration (IC50) values are shown for each cell line. (B) Downregulation of C-MYC upon JQ1 treatment (1 μM) at 6, 12, 24 and 48 
h in breast cancer cell lines, as determined by Western blot (left) and qRT-PCR (right). BRD4 expression levels do not change. *P<0.05; 
***P<0.001; ns: non-significant.
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by the use of JQ1 is higher than the one observed for 
the depletion of each factor (Supplementary Figure 2B 
and 2C). Thus, the observed growth-inhibitory effects 
of bromodomain inhibition in the luminal cells studied 
can be explained not only by the diminished expression 
of C-MYC, but also by a global reduction in the levels 
of transforming genes such as those exemplified by the 
PDZK1 and BCAS1 breast cancer oncogenes.
Bromodomain inhibition shows antitumoral 
activity and retards the onset of luminal breast 
tumors in the MMTV-PyMT luminal breast 
cancer mouse model
We next transferred our experiments from the in 
vitro and cell line assays described above to the in vivo 
setting in a mouse model of luminal breast cancer. The 
antitumoral activity of JQ1 was evaluated using MMTV-
PyMT transgenic mice that spontaneously develop 
multifocal luminal B breast tumors [16]. To assess the 
efficacy of JQ1 at inhibiting the growth of established 
tumors, we started the treatment when the total tumor 
volumes of each animal reached ~ 1,000-2,700 mm3 
(Figure 3A). We randomly selected eight MMTV-PyMT 
mice as the control group treated with vehicle and another 
eight for JQ1 treatment (25 mg/kg). Tumor volume was 
monitored every 2-3 days. The lack of toxicity of the drug 
was found under the described conditions. The use of the 
BET bromodomain inhibitor was significantly associated 
with the development of smaller breast tumors than those 
that occurred in the control group (Figure 3B).
Finally, once we had established the efficacy of 
JQ1 at inhibiting the growth of established luminal breast 
tumors, we considered whether the drug not only had a 
Figure 2: Expression microarray analyses identify PDZK1 and BCAS1 as breast cancer oncoproteins downregulated 
by JQ1 treatment in human luminal breast cancer cell lines. (A) Flowchart of the expression microarray experiment. (B) qRT-
PCR validation of the microarray results for PDZK1 and BCAS1. (C) Downregulation of PDZK1 and BCAS1, determined by qRT-PCR, 
upon JQ1 use at different times. *P<0.05; **P<0.01; ***P<0.001.
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therapeutic, but also a preventive effect. The impact of 
BET bromodomain inhibition on preventing spontaneous 
mammary tumors that naturally arise in MMTV-PyMT 
mice was evaluated as described in Figure 3C. Briefly, 
the MMTV-PyMT mice were randomly divided into 
a treatment group (25 mg/kg, n=5) and a vehicle group 
(n=7). JQ1 was administered when mice were 4 weeks 
old and when no palpable or visible tumors existed. Tumor 
volume was monitored every 2-3 days. We observed 
that those MMTV-PyMT mice receiving the BET 
bromodomain inhibitor experienced later onset of breast 
cancer and developed significantly smaller tumors (Figure 
3D). Most notably, the treatment with JQ1 increased the 
overall survival of the MMTV-PyMT mice in comparison 
to those that received the mock treatment (Figure 3E). 
These results suggest that bromodomain inhibitors 
may exert a protective anti-tumorigenic effect against 
tumorigenesis, and that it would be worthwhile exploring 
the benefits of using them in the context of individuals 
with a high-risk of developing breast cancer and other 
malignancies.
DISCUSSION
Herein, we have analyzed the effect of the BET 
bromodomain inhibitor JQ1 in the context of luminal 
breast cancer in mouse models and human cells. Our 
results highlight how using the epigenetic drug yields 
remarkable antitumoral effects against luminal breast 
tumors in association with the downregulation of its 
known target C-MYC. These findings represent the 
first demonstration in vivo of the antiproliferative 
characteristics of this small molecule for this particular 
mammary cancer subtype. Importantly, the impact of 
JQ1 on the transcriptional landscape of the treated breast 
cancer cells extends beyond the depletion of C-MYC to 
affect hundreds of other genes. Among the candidates 
that can also mediate the growth inhibitory action of 
the compound, we have further characterized the JQ1-
associated downregulation of two important breast cancer 
oncogenes, BCAS1 and PDZK1. Our findings suggest that 
the anticancer effect observed for the BET bromodomain 
inhibitor involves many cellular and signaling pathways 
Figure 3: JQ1 treatment inhibits growth and prevents formation of luminal breast tumors in the MMTV-PyMT mouse 
model. (A) Design of the “curative treatment experiment”. (B) Tumor volume monitored over time in vehicle- and JQ1-treated MMTV-
PyMT mice. **P<0.01. (C) Design of the “prevention treatment experiment”. (D) Tumor volume monitored over time in vehicle- and 
JQ1-treated MMTV-PyMT mice. *P<0.05. (E) Kaplan-Meier survival curves for vehicle- and JQ1-treated MMTV-PyMT mice. Statistical 
differences tested with Log Rank (Mantel-Cox) test.
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and that the target genes can have tumor-type-specific 
patterns.
Our study also provides at least another interesting 
indication of the significant role of bromodomain proteins 
in tumorigenesis. We show that the use of the BET 
bromodomain inhibitor JQ1 prevents the development 
of breast cancer in mice. Our results demonstrate 
that the administration of JQ1 in the MMTV-PyMT 
significantly delayed the development of breast tumors 
and increased overall survival. Notably, the treatment of 
the mice with the epigenetic drug did not result in any 
evident adverse developmental consequences in these 
animals. These results, in addition to identifying a key 
role for bromodomain proteins in breast carcinogenesis, 
are encouraging as proof-of-concept that these types of 
compound may be useful in cancer chemoprevention 
strategies. In this regard, it would be worth pre-clinically 
testing the efficacy of BET bromodomain inhibitors in 
diminishing the onset of disease in women at high-risk of 
developing breast cancer, such as those that are carriers 
of germline mutations in the tumor suppressor and DNA 
repair genes BRCA1 and BRCA2. Interestingly, recent 
findings indicate that the presence of BRCA1 mutations 
is associated with augmented proliferation of luminal 
progenitor cells [29–32] and, thus, JQ1 could be used in 
pre-neoplastic tissue to block these hyperactive cells in 
their course towards full cancer development.
Finally, it is relevant to mention that although JQ1 
was the first-in-class BET bromodomain inhibitor, other 
drugs have been developed with similar or identical targets 
[6], such as I-BET151 [33], RVX-208 [34] and OTX015 
[15, 35], that can work in the breast cancer models 
studied and that could be tested. However, all these drugs 
have common features that interfere with the binding of 
bromodomain protein to their targets in normal and cancer 
cells, so far with little specificity. It is in this context 
that the necessity might emerge for a more personalized 
cancer treatment using BET bromodomain inhibitors 
based on the genomic alterations observed in individual 
patients. In this regard, the presence of point mutations, 
gene copy number alterations and translocations involving 
histone acetyltransferases, histone deacetylases and the 
bromodomain proteins themselves [36–38] could be 
important biomarkers for predicting the true therapeutic 
potential of these drugs.
MATERIALS AND METHODS
Cell lines
The human luminal breast cancer cell lines MCF-
7 and T47D used in this study were purchased from the 
American Type Culture Collection (ATCC). MCF-7 and 
T47D were cultured in DMEM and RPMI, respectively. 
Both mediums were supplemented with 10% fetal bovine 
serum and the cells were grown at 37°C and 5% CO2.
Dose-response assays
For dose-response assays, 3000 cells were seeded 
in 96-well plates. The optimal number of cells for each 
experiment was determined to ensure that each one was 
in growth phase at the assay endpoint. After overnight 
incubation, experimental medium containing increasing 
concentrations of JQ1 was added into each well. Cell 
viability assay was determined at 96 h after treatment, 
by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay. Briefly, MTT reagent 
was added and incubated for 3 h, after which the cells 
were lysed for 16 h with MTT lysis buffer (50% N-N 
dimethylformamide, 20% sodium dodecyl sulfate, 2.5% 
glacial acetic acid, 2.1% 1N HCl, at pH 4.7). Plates were 
measured at 560 nm using a spectrophotometer.
RNA isolation and quantitative PCR
Total RNA was extracted using a Maxwell® RSC 
simply RNA Cell Kit (Promega). Real-time PCR reactions 
were performed following the methods for use of SYBR 
Green (Applied Biosystems). GAPDH was used as an 
endogenous control to enable normalization. Specific 
primers are detailed in Supplementary Table 2.
Immunoblotting assays
Total protein from cells was extracted with 
Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8, 
25% glycerol, 2% SDS, 0.01% bromophenol blue, 5% 
β-mercaptoethanol). Specific antibodies against target 
proteins are detailed in Supplementary Table 2.
Gene expression microarray analysis
For expression array analysis, twelve RNA samples 
were extracted using a Maxwell® RSC simply RNA 
Cell Kit (Promega) and sent to the CRG Genomics Unit 
(Barcelona). RNA was extracted from three independent 
biological replicates treated with JQ1 (1 μM 24h) and 
three independent biological replicates treated with 
vehicle (DMSO). Expression data from the Agilent Gene 
Expression one-color chip human 8x60K microarrays 
were analyzed with the Bioconductor limma library 
v3.28 in the R v3.3.0 statistical environment. Briefly, 
the extracted intensities were background-corrected by 
applying the normexp calculation. The background-
corrected log2-transformed values were quantile-
normalized to make data from all arrays comparable. 
After filtering out control and low-level expression probes, 
we applied empirical Bayes statistics within the limma 
package for two class comparisons in order to calculate the 
difference in expression between conditions. Transcripts 
with significant differences (absolute logFC > 1 and 
adjusted p < 0.05) were considered for further analysis. 
The gene functional annotation analysis was performed 
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by computing gene overlapping with GSEA KEGG and 
GO signature collections. We used a hypergeometric test 
to assess the overrepresentation of specific functions in 
the gene set tested. The associated hypergeometric p-value 
was corrected for multiple hypotheses testing according to 
Benjamini and Hochberg. Finally, we selected the 10 most 
significant over-represented terms with a False Discovery 
Rate q-value below 0.05.
Short hairpin interference
Two different sequence gene specific hairpin RNA 
molecules (shRNAs) for C-MYC, PDZK1, or BCAS1 
mRNA were designed and transduced into MCF7 and 
T47D breast cancer cell lines. shRNA against the MSS2 
yeast protein (not present in mammals) was used as 
scrambled (control). shRNAs and scramble sequences can 
be found in Supplementary Table 2. All shRNA molecules 
were ligated into pLVX-shRNA2-ZsGreen plasmid from 
Clontech, using BamHI and EcoRI restriction enzymes. 
Each shRNA-encoding plasmid (10 μg) was mixed with 
7.5 μg of ps-PAX2 and 2.5 μg of PMD2.G plasmid in 1 
ml JetPRIME buffer and 50 μl of JetPRIME. Upon 10 
min of RT incubation, the transfection mix was added 
dropwise on a 10 cm culture plate containing HEK293-
TLV lentiviral packaging cells at 80% confluence. After 72 
h, medium with high-titer lentiviral particles was 0.45 μm 
filtered. MCF7 and T47D target cells were cultured in virus 
containing medium for 24 h. As transduction efficiencies 
were higher than 95%, and in order to avoid the cloning 
bias-effect, we chose working with a pool of cells with 
high expression of shRNA constructs. Cell proliferation 
was determined by the MTT assay. A total of 1000 cells 
of MCF7 or 2000 cells of T47D were plated onto 96-well 
plates in the corresponding medium with vehicle or with 
1μM JQ1. MTT was added on 8 consecutive days at a final 
concentration of 5 mg/mL and further procedure was done 
as described previously.
Mouse model
MMTV-PyMT+ male mice (FVB/Nj strain) were 
kindly provided by Dr. Gonzalez-Suarez (IDIBELL, 
Barcelona, Spain). Transgenic females were obtained by 
breeding FVB/Nj females with PyMT+ transgenic males. 
All mouse experiments were approved by the IDIBELL 
Animal Care and Use Committee and performed in 
accordance with the guidelines of The International 
Guiding Principles for Biomedical Research Involving 
Animals, developed by the Council for International 
Organizations of Medical Sciences (CIOMS).
Curative in vivo treatment
When the total tumor volume of each animal reached 
~ 1,000-2,700 mm3, PyMT+ female mice were randomized 
into a JQ1 treatment group (25 mg/kg, n=8) and a vehicle 
(control) group (n=8). JQ1 or vehicle (1:10 DMSO:10% 
hydroxypropyl β cyclodextrin) was administered daily 
intraperitoneally for 11 doses on a 5-days-on/2-days-off 
dosing schedule. Tumor growth was monitored every 2-3 
days by measuring tumor width (W) and length (L). Tumor 
volume, V, was then estimated from the formula V=π/6x 
(L x W2) and reported as the sum of all the tumor volumes 
for each animal and the mean and SEM of each mouse 
group. Two days after completion of the treatment, mice 
were euthanized.
Preventive in vivo treatment
PyMT+ female mice were randomly divided into 
a JQ1 treatment group (25 mg/kg, n=5) and a vehicle 
(control) group (n=7). When mice were 4 weeks old 
and no palpable or visible tumors were present, JQ1 or 
vehicle (1:10 DMSO:10% hydroxypropyl β cyclodextrin) 
were administered intraperitoneally daily for 3 weeks on 
a 5-days-on/2-days-off dosing schedule. Tumor growth 
was monitored every 2-3 days by measuring tumor width 
(W) and length (L). Tumor volume, V, was then estimated 
from the formula V=π/6x(L x W2). Mice were euthanized 
when the total 10 tumor volume per animal was greater 
than 4,000 mm3.
Statistical analysis
Real Time Quantitative PCR results were 
statistically analyzed with a Two samples T test, in the case 
where JQ1 treated and not treated samples were compared 
an din the case of shRNA depletion; with a Tukey Multiple 
comparasions of mean test, in time course experiments 
cases. Concerning tumor and cell growth experiments we 
used an AUC Vardi test with 1000 permutations. Kaplan-
Meier survival curves statistical differences were tested 
with Log Rank (Mantel-Cox) test. P values less than 
0.05 were considered significant (*P>0.05; **P>0.005; 
***P>0.001; n.s = no significance).
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